Government-Owned Inventions; Availability for Licensing, 13460 [2017-04834]

Download as PDF 13460 Federal Register / Vol. 82, No. 47 / Monday, March 13, 2017 / Notices Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435– 1164, custerm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Neural Regulation of Cancer. Date: March 29, 2017. Time: 12:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Rolf Jakobi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6187, MSC 7806, Bethesda, MD 20892, 301–495– 1718, jakobir@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 16– 218: Provocative Questions in Pediatric Cancer. Date: April 4, 2017. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Charles Morrow, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892, 301–451– 4467, morrowcs@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. N6, A Novel, Broad, Highly Potent HIVSpecific Antibody DEPARTMENT OF HEALTH AND HUMAN SERVICES Description of Technology The N6 antibody has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01class antibodies. N6 was shown in preclinical studies to neutralize approximately 98 percent of HIV isolates tested. The studies also demonstrate that N6 neutralizes approximately 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently. Its breadth and potency makes N6 a highly desirable candidate for development in therapeutic or prophylactic strategies. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. National Institutes of Health Potential Commercial Applications [FR Doc. 2017–04807 Filed 3–10–17; 8:45 am] BILLING CODE 4140–01–P mstockstill on DSK3G9T082PROD with NOTICES National Institutes of Health, HHS. Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious SUMMARY: VerDate Sep<11>2014 17:49 Mar 10, 2017 Jkt 241001 [FR Doc. 2017–04834 Filed 3–10–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. • Neutralized 98 percent of HIV isolates tested. • Neutralized 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently. Development Stage: Pre-Clinical. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID; Investigator Initiated Program Project Applications (P01). Date: March 29, 2017. Time: 11:00 a.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. • HIV therapeutic • HIV prophylactic Government-Owned Inventions; Availability for Licensing ACTION: Dated: March 3, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. Competitive Advantages Dated: March 7, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. AGENCY: Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng, all of NIAID. Publications: Huang, Jinghe, et al. ‘‘Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth.’’ Immunity 45.5 (2016): 1108–1121. Intellectual Property: HHS Reference No. E–131–2015 et seq.—US provisional application 62/136,228, US provisional application 62/250,378, and PCT application PCT/US2016/023145. Licensing Contact: Chris Kornak, 240– 627–3705, chris.kornak@nih.gov. Collaborative Research Opportunity: The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further codevelop this technology. For collaboration opportunities, please contact Chris Kornak, 240–627–3705, chris.kornak@nih.gov. PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\13MRN1.SGM 13MRN1

Agencies

[Federal Register Volume 82, Number 47 (Monday, March 13, 2017)]
[Notices]
[Page 13460]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04834]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

N6, A Novel, Broad, Highly Potent HIV-Specific Antibody

Description of Technology

    The N6 antibody has evolved a unique mode of binding that depends 
less on a variable area of the HIV envelope known as the V5 region and 
focuses more on conserved regions, which change relatively little among 
HIV strains. This allows N6 to tolerate changes in the HIV envelope, 
including the attachment of sugars in the V5 region, a major mechanism 
by which HIV develops resistance to other VRC01-class antibodies. N6 
was shown in pre-clinical studies to neutralize approximately 98 
percent of HIV isolates tested. The studies also demonstrate that N6 
neutralizes approximately 80 percent of HIV isolates which were 
resistant to other antibodies of the same class, and does so very 
potently. Its breadth and potency makes N6 a highly desirable candidate 
for development in therapeutic or prophylactic strategies.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     HIV therapeutic
     HIV prophylactic

Competitive Advantages

     Neutralized 98 percent of HIV isolates tested.
     Neutralized 80 percent of HIV isolates which were 
resistant to other antibodies of the same class, and does so very 
potently.
    Development Stage: Pre-Clinical.
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, 
Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng, all of NIAID.
    Publications: Huang, Jinghe, et al. ``Identification of a CD4-
binding-site antibody to HIV that evolved near-pan neutralization 
breadth.'' Immunity 45.5 (2016): 1108-1121.
    Intellectual Property: HHS Reference No. E-131-2015 et seq.--US 
provisional application 62/136,228, US provisional application 62/
250,378, and PCT application PCT/US2016/023145.
    Licensing Contact: Chris Kornak, 240-627-3705, 
chris.kornak@nih.gov.
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further co-develop this technology. For 
collaboration opportunities, please contact Chris Kornak, 240-627-3705, 
chris.kornak@nih.gov.

    Dated: March 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-04834 Filed 3-10-17; 8:45 am]
 BILLING CODE 4140-01-P